Grail Inc
NASDAQ:GRAL

Watchlist Manager
Grail Inc Logo
Grail Inc
NASDAQ:GRAL
Watchlist
Price: 97.46 USD -2.34% Market Closed
Market Cap: 3.8B USD

Grail Inc
Long-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Grail Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Grail Inc
NASDAQ:GRAL
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Long-Term Debt
$63B
CAGR 3-Years
1%
CAGR 5-Years
-5%
CAGR 10-Years
7%
Gilead Sciences Inc
NASDAQ:GILD
Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Long-Term Debt
$52.4B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Long-Term Debt
$2.7B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
21%
No Stocks Found

Grail Inc
Glance View

Market Cap
3.5B USD
Industry
Biotechnology

Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

GRAL Intrinsic Value
26.42 USD
Overvaluation 73%
Intrinsic Value
Price

See Also

What is Grail Inc's Long-Term Debt?
Long-Term Debt
0 USD

Based on the financial report for Dec 31, 2024, Grail Inc's Long-Term Debt amounts to 0 USD.

Back to Top